Vasculitis & polymyalgia rheumatica
Efficacy and safety of low- versus high-dose glucocorticoid regimens for induction of remission of anti-neutrophil cytoplasm antibody-associated vasculitis: a systematic review and meta-analysis
Pooled result · Remission (primary efficacy outcome)Result — go to the resultRR for remission 0.98 95% CI 0.95–1.02Authors' conclusion
Studies with low-dose GC regimens in AAV are associated with fewer infections while obtaining equivalent efficacy.
Study context
- Population
- Patients with AAV in clinical studies using a GC-based induction protocol3 RCTs and 2 observational studies
- Participants
- 1,145 patients
- Comparison
- Low-dose vs high-dose GC regimens for remission induction
- Low-dose GCn = 543
- High-dose GCn = 602reference
- Outcome
- Remission (primary efficacy outcome)
Methodological detailsrandom effects model
- Random effects model
Pooled result
As reported in the abstract
RR for remission
0.98
95% CI 0.95–1.02
P = 0.37
Low-dose GCvs High-dose GC
RR for remission 0.98 (95% CI 0.95–1.02); P = 0.37
Further pooled results
| Outcome | Risk difference (95% CI) | P value | |
|---|---|---|---|
| RelapseI2 = 12% · non-inferior | 0.03 (−0.01 to 0.06) | P = 0.15 | |
| −0.0500.050.1Difference (linear scale) |
Safety
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| InfectionI2 = 65% | 0.60 (0.39–0.91) | P = 0.02 | |
| 0.20.5125Relative risk (log scale) |
Original publication
Efficacy and safety of low- versus high-dose glucocorticoid regimens for induction of remission of anti-neutrophil cytoplasm antibody-associated vasculitis: a systematic review and meta-analysis. Scand J Rheumatol. Published 20 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →